Arion, D
Corradi, J P
Tang, S
Datta, D
Boothe, F
He, A
Cacace, A M
Zaczek, R
Albright, C F
Tseng, G
Lewis, D A
Article History
Received: 28 May 2014
Revised: 14 October 2014
Accepted: 12 November 2014
First Online: 6 January 2015
Competing interests
: DAL currently receives investigator-initiated research support from Bristol-Myers Squibb and Pfizer, and in 2012–2014 served as a consultant in the areas of target identification and validation, and new compound development to Autifony, Bristol-Myers Squibb, Concert Pharmaceuticals and Sunovion. All other authors declare no conflicts of interest.